Explore all the latest information in myelodysplastic syndromes, arranged by key congresses and meetings. Listed below are recently updated congresses and meetings.
How can we improve on current risk stratification in MDS?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Uwe Platzbecker, University of...
Results from the phase II P-2001 study on pevonedistat plus azacytidine for high-risk MDS
To further explore the clinical efficacy and safety of pevo in patients with high-risk MDS, CMML, or low-blast...
What are the challenges in diagnosing MDS?
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub spoke to Aziz Nazha, Cleveland Clinic, Cleveland, US. We asked:...
Targeted therapeutics in MDS – what’s the current state of play?
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub podcast channel spoke to Dr David Sallman,...
Practice-changing abstracts at EHA 2020
The MDS Hub was pleased to speak to Steering Committee Chair Theo De Witte, Radboudumc, Nijmegen, NL, about practice-changing abstracts from the 25th European...
How can cytogenetics predict response to venetoclax and azacitidine in MDS?
During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Jacqueline S. Garcia,...
What is the benefit of adding pevonedistat to azacitidine in patients with high-risk MDS or AML?
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the MDS Hub was delighted to...
Magrolimab plus azacytidine in patients with myelodysplastic syndromes and acute myeloid leukemia
During the American Society of Clinical Oncology (ASCO) Virtual Meeting 2020, David Sallman from the...
Society of Hematologic Oncology
American Society of Clinical Oncology
American Society of Hematology
European Hematology Association
European Society for Blood and Marrow Transplantation